

Neuroscience Research Australia

(A Company Limited By Guarantee)

ABN 94 050 110 346

General Purpose Financial Report

For the year ended 31 December 2025

Contents

Directors' Report	3
Auditor's Independence Declaration	8
Consolidated Statement of Profit or Loss and Other Comprehensive Income	9
Consolidated Statement of Financial Position	10
Consolidated Statement of Changes in Members' Funds	11
Consolidated Statement of Cash Flows	12
Notes to the Consolidated Financial Statements	13
Directors' Declaration	26
Declaration by Responsible Officer in Respect of Fundraising Appeals	27
Independent Auditor's Report	28

Directors' Report

The Directors present their report together with the consolidated financial statements of the Group comprising Neuroscience Research Australia ('the Company') and its controlled entities, for the year ended 31 December 2025 and the auditor's report thereon.

1. Directors

The names and details of Directors' of the Group in office at any time during or since the end of the financial period are:

Jennifer Alexander Appointed Experience	Nominee of Minister for Health Director in January 2013 and resigned in May 2025 Pro Chancellor of the University of New South Wales and a member of the UNSW Council.
--	--

Catherine Fritz-Kalish AM Appointed Experience	Independent Director Director in August 2024 Co-Founder and Managing Director of Global Access Partners Pty Ltd.
---	--

Georgina Hold	Nominee of South Eastern Sydney Local Health District Director in November 2025 Director of Research – South Eastern Sydney Local Health District
----------------------	---

Cheryl Jones Appointed Experience	Nominee of University of New South Wales Director in November 2024 Dean - Medicine and Health at the University of New South Wales.
--	---

Jo Karnaghan Appointed Experience	Nominee of South Eastern Sydney Local Health District Director in February 2024 and resigned in February 2026 Former Director of Clinical Governance & Medical Services, South Eastern Sydney Local Health District.
--	--

James Linklater OAM Appointed Experience	Independent Director Director in August 2024 Chief Executive Officer of Castlereagh Imaging and Illawarra Radiology Group.
---	--

James MacNevin Appointed Experience	Independent Director & Chair Director in May 2022 Chief Operating Officer, Perpetual Group. He was appointed Chair in June 2022.
--	--

Cheryl Maley Appointed Experience	Independent Director Director in February 2024 Chief Executive Officer and Managing Director of Starpharma Holdings Ltd.
--	--

Directors' Report

Clyde McConaghy*

Appointed
Experience

Independent Director

Director in August 2013 and again in June 2019 and resigned in May 2025
Company Director on a number of public listed and private companies.

Peter Ricketts

Appointed
Experience

Independent Director

Director in February 2025
Experienced Board Director with extensive background in finance, risk and strategy.

Sven Rogge

Appointed
Experience

Nominee of University of New South Wales

Director in June 2022
Dean of Science at the University of New South Wales.

Norbet Schweizer OAM*

Appointed
Experience

Independent Director

Director in November 2015 and again in May 2022 and resigned in May 2025
Former founding partner of Schweizer Kobras, Lawyers and Notaries and is an accredited business law specialist.

Barry Shepherd PSM*

Appointed
Experience

Independent Director

Director in November 1991 and again in May 2022 and resigned in May 2025
Consultant and a former Director Corporate Services, South Eastern Sydney & Illawarra Area Health Service.

David Stanton

Appointed
Experience

Independent Director

Director in August 2024
Head of Australian Healthcare Research with Jefferies Australia.

Steve Tucker

Appointed
Experience

Director

Director in November 2023
Chair and Founding Partner at Koda Capital.

Chris White

Appointed
Experience

Nominee of Southern Eastern Sydney Local Health District

Director in June 2022 and resigned in August 2025
Senior Staff Endocrinologist, Prince of Wales Hospital and Conjoint Professor, University of New South Wales.

*See reference to Governing Council on page 5

Directors' Report

a) *NeuRA Governing Council*

The Governing Council was a Board Committee and oversaw the operations and functions of the NeuRA Division from February 2018 to May 2022, when the Governing Council again became the Board responsible for the governance of NeuRA. A number of Governing Councillors* were Directors of NeuRA prior to February 2018.

b) *Finance, Risk, Audit and Compliance (FRAC) Committee*

The FRAC Committee is a Board Committee and oversees all financial, risk, audit, and compliance aspects of NeuRA. This committee provided oversight of the activities of the Company, Neuroscience Research Australia, and its subsidiaries, Neuroscience Research Australia Foundation, and the Schizophrenia Research Institute. The members of the FRAC Committee during the year were: Jennifer Alexander (Chair to February 2025), Stephen Blackman, Barry Shepherd (to February 2025), and Peter Ricketts (Chair from April 2025).

c) *Investment Committee*

The Investment Committee oversees and makes investment recommendations to the Boards of Directors to support NeuRA's research and associated infrastructure. This committee provided oversight of the activities of the Company, Neuroscience Research Australia, and its subsidiaries, Neuroscience Research Australia Foundation, and the Schizophrenia Research Institute. The members of the Investment Committee during the year were: Clyde McConaghy (Chair to May 2025) and Steve Tucker (Chair from May 2025), David Stanton and Murray Brewer.

d) *Non-Executive Directors*

Non-executive directors were not paid any compensation during the period.

Directors' meetings

The number of Directors' meetings and number of meetings attended by each of the directors of the Group during the financial period are:

Directors	A	B
Dr Jennifer Alexander	2	2
Catherine Fritz-Kalish AM	4	3
Prof Georgina Hold	1	1
Prof Cheryl Jones	4	3
Dr Jo Karnaghan	4	3
Dr James Linklater OAM	4	3
Cheryl Maley	4	3
Mr James MacNevin	4	4
Mr Clyde McConaghy	2	2
Mr Peter Ricketts	4	3
Prof Sven Rogge	4	3
Mr Norbet Schweizer OAM	2	2
Mr Barry Shepherd PSM	2	2
Mr David Stanton	4	4
Mr Steve Tucker	4	4
A/Prof Chris White	3	1

A - Number of meetings held during the time the director held office during the period

B - Number of meetings attended

Company secretary

Felicity Forsyth was appointed Company Secretary in November 2022.

Directors' Report

2. Principal activities

The principal activities of the Group during the financial period were the conduct of medical research, the development of medical research facilities and fundraising activities. Included within the Group are Neuroscience Research Australia, Neuroscience Research Australia Foundation and Schizophrenia Research Institute.

There were no significant changes in the nature of the activities of the Group during the year.

3. Results of operations

The loss of the Group is \$6,017,318 (2024: surplus of \$2,799,377).

During the year the Group received research grants from the National Health and Medical Research Council and various other grant giving bodies to fund research programs and grants from the State Government in respect of research infrastructure. The Group also received donations and conducted fundraising activities, the proceeds of which were used to fund current and future medical research activities.

4. Significant changes in the state of affairs

In June 2025, StandingTall Pty Ltd was voluntarily deregistered due to a strategic decision. Additionally, in 2025 the Board approved a plan to commence the wind-up of the Foundation and its Public Ancillary Fund, with activities to transition to a Fundraising Committee of the NeuRA Board. The Foundation is expected to continue operations during the wind-up period.

5. Events subsequent to reporting date

In March 2026, the Group deregistered the Schizophrenia Research Institute (SRI) as a subsidiary.

Other than the matters discussed above, there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the directors of the Group, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group, in future financial years.

6. Likely developments

The entity will continue to pursue the principal activities of the Group during the financial period being the conduct of medical research, the development of medical research facilities and fundraising activities.

7. Insurance of officers and directors

During the financial year, insurance for Directors', the secretary and certain Officers of the entity was provided by CGU Insurance. During or since the financial year, the entity has not indemnified or made a relevant agreement to indemnify an officer or auditor of the entity or of any related body corporate against a liability incurred as such an officer or auditor. In addition, the entity has not paid or agreed to pay a premium in respect of a contract insuring against a liability incurred by an officer or auditor.

8. Environmental regulation

The entity's operations include research on genetically modified laboratory animals and as such complies with the Office of Gene Technology Regulator (OGTR) which is a part of the Commonwealth Government.

9. Objectives and strategy

The Group's principal activities comprise conducting medical research in the neurosciences and undertaking fundraising to support this research. The Group's work spans discovery, translational, and clinical research, undertaken in partnership with the university, health district, industry, and the community.

The Group's vision is to improve the health and lives of people living with brain disorders. This vision is pursued through the *NeuRA Forward 2025–2030* Strategic Plan, which focuses on three missions:

- protecting brain health across the lifespan,
- developing innovative therapeutics and interventions to maximise brain function, and

Directors' Report

- advancing precision diagnostics through genomics, neuroimaging, artificial intelligence, and data-driven tools.

Progress is measured through indicators including scientific excellence, competitive research funding, clinical translation outcomes, community impact, strengthened partnerships, innovation and commercialisation activity, and organisational capability. These measures incorporate attracting high-quality researchers, securing significant grant and philanthropic funding, and collaborating with clinical and industry partners to translate research into improved health outcomes for the community.

10. Members liability


The Company is a company limited by guarantee and without share capital. In accordance with the constitution of the Company, every member of the Company undertakes to contribute an amount limited to \$20 per member to the assets of the Company in the event of it being wound up while he or she is a member or within one year afterwards for payment of the debts and liabilities of the Company contracted before he or she ceases to be a member and of the costs, charges, and expenses of winding up and for the adjustment of the rights of the contributories among themselves. The total amount that members of the Company are liable to contribute if the Company is wound up is \$200 (2024: \$300).

11. Auditor's independence declaration under subdivision 60-C section 60-40 of *Australian Charities and Not-for-Profits Commission Act 2012*

The Lead Auditor's independence declaration is set out on page 8 and forms part of the Directors' report for the financial year ended 31 December 2025.

Signed in accordance with a resolution of the directors:


James MacNevin
Chair


Prof Mathew Kiernan AM
Chief Executive Officer

Dated at Sydney this 14th day of May 2026.



Auditor's Independence Declaration under subdivision 60-C section 60-40 of Australian Charities and Not-for-profits Commission Act 2012

To the Directors of Neuroscience Research Australia

I declare that, to the best of my knowledge and belief, in relation to the audit of Neuroscience Research Australia for the financial year ended 31 December 2025 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- ii. no contraventions of any applicable code of professional conduct in relation to the audit.

KPMG

Warwick Shanks

Partner

Sydney

14 May 2026

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the year ended 31 December 2025

	Note	2025 \$	2024 \$
REVENUE			
Grant revenue	4	17,015,376	19,567,005
Donations and fundraising	5	9,341,432	14,910,311
Sale of goods		11,116	64,745
Conference revenue		23,715	72,862
Laboratory services		188,377	351,059
Sponsorship income		40,154	242
Other revenue from ordinary activities		588,687	193,676
Other income		840,000	-
TOTAL REVENUE		28,048,857	35,159,900
EXPENSES			
Personnel expenses	6	(22,763,910)	(21,160,746)
Depreciation expenses	7	(2,176,572)	(2,315,418)
Other expenses	8	(12,680,067)	(13,047,127)
TOTAL EXPENSES		(37,620,549)	(36,523,291)
LOSS FROM OPERATIONS		(9,571,692)	(1,363,391)
Finance income	9	3,718,050	4,336,268
Finance costs	9	(163,676)	(173,500)
NET FINANCE INCOME		3,554,374	4,162,768
(LOSS)/PROFIT FOR THE YEAR		(6,017,318)	2,799,377
Other comprehensive income		-	-
TOTAL COMPREHENSIVE (LOSS)/INCOME		(6,017,318)	2,799,377

Consolidated Statement of Financial Position

As at 31 December 2025

	Note	2025 \$	2024 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	10	6,186,274	5,319,814
Trade and other receivables	11	2,234,266	5,457,149
Other financial assets	12	38,292,938	40,970,363
TOTAL CURRENT ASSETS		46,713,478	51,747,326
NON-CURRENT ASSETS			
Property, plant and equipment	13	53,813,939	52,015,447
TOTAL NON-CURRENT ASSETS		53,813,939	52,015,447
TOTAL ASSETS		100,527,417	103,762,773
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	14	6,950,356	2,968,452
Employee benefits	15	1,835,584	2,991,547
Deferred revenue		2,406,499	2,401,790
TOTAL CURRENT LIABILITIES		11,192,439	8,361,789
NON-CURRENT LIABILITIES			
Employee benefits	15	299,987	348,675
TOTAL NON-CURRENT LIABILITIES		299,987	348,675
TOTAL LIABILITIES		11,492,426	8,710,464
NET ASSETS		89,034,991	95,052,309
MEMBERS' FUNDS			
Retained surplus - Schizophrenia Research Institute		1,288	1,408
Retained surplus		89,033,703	95,050,901
TOTAL MEMBERS' FUNDS		89,034,991	95,052,309

Consolidated Statement of Changes in Members' Funds

For the year ended 31 December 2025

	Retained surplus - Schizophrenia Research Institute \$	Retained surplus \$	Total members funds \$
BALANCE AT 1 JANUARY 2024	1,529	92,251,404	92,252,933
COMPREHENSIVE INCOME			
Profit for the year	(121)	2,799,497	2,799,376
TOTAL COMPREHENSIVE INCOME	(121)	2,799,497	2,799,376
BALANCE AT 31 DECEMBER 2024	1,408	95,050,901	95,052,309
COMPREHENSIVE INCOME			
Loss for the year	(120)	(6,017,198)	(6,017,318)
TOTAL COMPREHENSIVE INCOME	(120)	(6,017,198)	(6,017,318)
BALANCE AT 31 DECEMBER 2025	1,288	89,033,703	89,034,991

Consolidated Statement of Cash Flows

For the year ended 31 December 2025

	2025	2024
Note	\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES		
Grants received	21,944,508	19,826,788
Receipts from donations and fundraising	9,341,432	14,910,312
Receipts from customers	1,777,254	697,629
Payments to suppliers and employees	(34,453,466)	(33,528,763)
NET CASH (USED IN)/FROM OPERATING ACTIVITIES	(1,390,272)	1,905,966
CASH FLOWS FROM INVESTING ACTIVITIES		
Net proceeds/(investment in) other financial assets	4,095,465	(1,306,243)
Acquisitions of property, plant and equipment	(4,024,584)	(243,818)
Proceeds from sale of property, plant and equipment	49,519	-
Interest received	203,534	297,087
Dividends received from investments	1,524,707	1,443,124
Franking credits	408,091	-
NET CASH FROM INVESTING ACTIVITIES	2,256,732	190,150
NET INCREASE IN CASH AND CASH EQUIVALENTS		
	866,460	2,096,116
Cash and cash equivalents at the beginning of the financial year	5,319,814	3,223,698
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	6,186,274	5,319,814
10		

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

Note 1 Reporting entity

Neuroscience Research Australia (the 'Company') is a company limited by guarantee, incorporated and domiciled in Australia. The Group's registered office is at Margarete Ainsworth Building 139 Barker St, Randwick, NSW, 2031.

These consolidated financial statements comprise the Company and its subsidiaries (together referred to as the 'Group').

The Group is a not-for-profit entity and is primarily involved in the conduct of medical research, the development of medical research facilities and fundraising activities.

Note 2 Basis of preparation

a) *Statement of compliance*

These consolidated financial statements are general purpose financial statements for distribution to the members and for the purpose of fulfilling the requirements of the *Australian Charities and Not-for-Profits Commission Act 2012*. They have been prepared in accordance with Australian Accounting Standards - Simplified Disclosures made by the Australian Accounting Standards Board and the *Australian Charities and Not-for-Profits Commission Act 2012*.

These consolidated financial statements were authorised for issue by the Board of Directors as of the date of the Directors Declaration.

b) *Basis of measurement*

The consolidated financial statements have been prepared on an accruals basis and are based on historical costs unless otherwise stated in the notes.

c) *Functional and presentation currency*

These consolidated financial statements are presented in Australian dollars, which is the Group's functional currency.

d) *Use of judgements and estimates*

In preparing these consolidated financial statements, management has made judgements and estimates that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

Details of the specific judgement, estimates and assumptions that have the most significant effects on the amounts recognised in the consolidated financial statements are summarised in the Notes.

e) *Going concern*

The consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activities and realisation of assets and settlement of liabilities in the ordinary course of business.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

Note 3 Material accounting policies

a) *Basis of consolidation*

i. **Subsidiaries**

Subsidiaries are entities controlled by the Group. The Group 'controls' an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account.

The acquisition of subsidiaries is accounted for using the purchase method of accounting, which involves allocating the cost of the business combination to the fair value of the assets acquired and the liabilities and contingent liabilities assumed at the date of acquisition.

Investments in subsidiaries held of the Group are accounted for at cost in the separate financial statements of the parent entity less any impairment charges. Dividends received from subsidiaries are recorded as a component of other revenues in the separate income statement of the parent entity, and do not impact the recorded cost of the investment. Upon receipt of dividend payments from subsidiaries, the parent will assess whether any indicators of impairment of carrying value of the investments in the subsidiary exist. Where such indicators exist, to the extent that the carrying value of the investment exceeds its recoverable amounts, an impairment loss is recognised.

ii. **Loss of control**

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary and other components of equity. Any resulting gain or loss is recognised in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

iii. **Transactions eliminated on consolidation**

Intra-group balances and transaction, and any unrealised income and expenses arising from intra-group transactions, are eliminated. Unrealised gains arising from transactions with associates are eliminated against the investment to the extent of the Group's interest in the investee. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment.

b) *Income tax*

The Group is a registered charity and is exempt from income tax under s50-5 of the *Income Tax Assessment Act 1997*.

c) *Property, plant and equipment*

i. **Recognition and measurement**

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

ii. **Subsequent expenditure**

Subsequent expenditure is capitalised only when it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

iii. Depreciation

Depreciation is calculated to write off the cost of items of property, plant and equipment less their estimated residual values using the diminishing value method over their estimated useful lives, and is generally recognised in profit or loss. Land is not depreciated.

The depreciation rates of property, plant and equipment for current and comparative periods are as follows:

	2025	2024
Leasehold improvements	3.03%	3.03%
Motor vehicles	22.50%	22.50%
Plant and equipment	20.00%	20.00%
Furniture and fittings	20.00%	20.00%
Buildings	3.03%	3.03%

Depreciation methods, depreciation rates and residual values are reviewed at each reporting date and adjusted if appropriate.

d) Financial instruments

i. Recognition and initial measurement

The Group recognises financial assets and financial liabilities when it becomes a party to the relevant contractual terms. Financial assets and liabilities are initially measured at fair value. For items not measured at fair value through profit or loss (FVTPL), directly attributable transaction costs are included in the initial measurement. Trade receivables without a significant financing component are measured at the transaction price.

ii. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as measured at amortised cost or FVTPL. Reclassification of financial assets only occurs when the Group changes its business model for managing those assets

Financial assets measured at amortised cost meet both of the following:

- They are held in a business model designed to collect contractual cash flows; and
- The contractual terms give rise to cash flows that are solely payments of principal and interest.

Financial assets not classified as measured at amortised cost as described above are measured at FVTPL. Financial assets in the "at amortised cost" category particularly include trade accounts receivable (not including factoring), cash and cash equivalents and other receivables. All other financial assets, including investment portfolios, are measured at FVTPL.

Financial assets - subsequent measurement

Financial assets at FVTPL

Measured at fair value at each reporting date. All fair value movements, including interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost

Measured using the effective interest method and reduced for impairment. Interest income, foreign exchange gains and losses, impairment losses and gains/losses on derecognition are recognised in profit or loss.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

Financial liabilities - classification and subsequent measurement

Financial liabilities are classified as either measured at amortised cost or FVTPL. Liabilities measured at FVTPL are recorded at fair value with changes recognised in profit or loss. All other financial liabilities, including trade payables and any borrowings, are measured at amortised cost using the effective interest method. Interest expense, foreign exchange differences, and gains or losses on derecognition are recorded in profit or loss.

iii. Derecognition

Financial assets

A financial asset is derecognised when the contractual rights to receive cash flows expire or those rights are transferred and substantially all risks and rewards of ownership are transferred. If substantially all risks and rewards are retained, the asset continues to be recognised.

Financial liabilities

A financial liability is derecognised when it is discharged, cancelled, or expires. If the terms are substantially modified, the original liability is derecognised and a new one is recognised. Any difference between the carrying amount of the liability extinguished and the consideration paid is recognised in profit or loss.

e) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of goods and services tax (GST), except:

- where the amount of GST incurred is not recoverable from the taxation authority, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense; or
- for receivables and payables which are recognised inclusive of GST.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables.

Cash flows are included in the statement of cash flows on a gross basis. The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified within operating cash flows.

f) Revenue from contracts with customers

Revenue from contracts with customers is recognised in the income statement when the significant risks and rewards of ownership have been transferred to the buyer. Revenue is recognised and measured at the fair value of the consideration or contributions received, net of goods and services tax ("GST") or similar taxes, to the extent it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured.

None of the revenue streams of the Group have any significant financing terms as there is less than 12 months between receipt of funds and satisfaction of performance obligations.

i. Grant income (research)

Government and other research grants are initially recorded as deferred income at fair value when it is reasonably certain the funds will be received and the Group will meet the grant conditions. If there are no conditions attached, income is recognised when the funds are received. Grants that reimburse the Group for specific costs are recognised as income in the same periods in which the related expenses are recognised.

ii. Grant income (non-research)

Grant income from agreements with clear and enforceable performance obligations are recognised as revenue when each obligation is satisfied.

Some obligations are fulfilled at a specific point in time, while others are delivered over the life of the contract. For obligations delivered over time, revenue is recognised based on either time or costs incurred, whichever best reflects the transfer of control.

If the grant has no performance obligations, the income is recognised when the funds are received.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

Revenue

Revenue recognition policy for revenue streams which are either not enforceable or do not have sufficiently specific performance obligations (AASB 1058).

iii. Grant income (non-research)

Assets arising from grants in the scope of AASB 1058 are recognised at their fair value when the asset is received. These assets are generally cash but may be property which has been donated or sold to the Group at significantly below its fair value.

Once the asset has been recognised, the Group recognises any related liability amounts (e.g. provisions, financial liabilities).

Once the assets and liabilities have been recognised then income is recognised for any difference between the recorded asset and liability.

Revenue from fundraising

1. Donations

Donations collected, including cash and goods for resale, are recognised as revenue when the Group gains control of the asset.

2. Bequests

Bequests are recognised when the Group is notified of an impending distribution or the bequest is received, whichever occurs earlier.

Revenue from bequests comprising shares or other property are recognised at fair value, being the market value of the shares or property at the date the Group becomes legally entitled to the shares or property.

Significant estimates and judgements relating to revenue

For many of the grant agreements received, the determination of whether the contract includes sufficiently specific performance obligations was a significant judgement involving discussions with several parties at the Group, review of the proposal documents prepared during the grant application phase and consideration of the terms and conditions.

Grants received by the Group have been accounted for under both AASB 15 and AASB 1058 depending on the terms and conditions and decisions made.

If this determination was changed then the revenue recognition pattern would be different from that recognised in this financial report.

g) Employee benefits

i. Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

ii. Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in profit or loss in the periods during which services are rendered by employees.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

iii. Other long-term employee benefits

The Group's net obligation in respect of long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods. That benefit is discounted to determine its present value. Remeasurements are recognised in profit or loss in the period in which they arise. The discount rate is the yield at the reporting date on government bonds that have maturity dates approximating the terms of the consolidated entity's obligations.

h) Finance income and finance costs

Finance income comprises interest income on funds invested, dividend income and changes in the fair value of financial assets at fair value through profit or loss. Interest income is recognised as it accrues in profit or loss using the effective interest method. Dividend income is recognised in profit or loss on the date on which the Group's right to receive payment is established.

	2025	2024
	\$	\$
Note 4 Grant revenue		
Research income	12,251,522	14,293,184
Infrastructure - MRSP	2,803,580	3,099,019
Infrastructure - UNSW	1,960,274	2,174,802
TOTAL GRANT REVENUE	17,015,376	19,567,005

	2025	2024
	\$	\$
Note 5 Donations and fundraising		
Bequests	1,359,500	6,270,186
Major gifts	5,722,434	5,084,531
Other	2,259,498	3,555,594
TOTAL DONATIONS AND FUNDRAISING	9,341,432	14,910,311

	2025	2024
	\$	\$
Note 6 Personnel expenses		
Wages, salaries and other personnel expenses	18,936,785	17,746,739
Contributions to superannuation funds	2,106,582	1,858,055
Increase in liability for annual leave	1,370,284	1,285,561
Increase in liability for long service leave	350,259	270,391
TOTAL PERSONNEL EXPENSES	22,763,910	21,160,746

	2025	2024
	\$	\$
Note 7 Depreciation expenses		
Depreciation	1,917,232	2,064,560
Amortisation	259,340	250,858
TOTAL DEPRECIATION EXPENSES	2,176,572	2,315,418

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

	2025	2024
	\$	\$
Note 8 Other expenses		
Insurance	307,397	325,060
Fundraising costs	863,993	595,793
Travel	1,017,417	940,122
Repairs and maintenance	741,480	611,842
Consultants	800,248	811,286
Conference expenses	191,676	140,968
Scholarships	484,311	379,441
Laboratory supplies	1,659,624	2,401,256
Other	2,994,461	2,853,758
Electricity	545,930	553,724
External consultants	1,774,776	1,617,799
Research	398,460	618,029
Software and licences	209,544	829,031
Cleaning	234,554	201,259
Contractor	456,196	167,759
TOTAL OTHER EXPENSES	12,680,067	13,047,127

	2025	2024
	\$	\$
Note 9 Net finance income		
FINANCE INCOME		
Interest income	203,534	297,087
Investment gain	1,581,717	2,596,057
Dividend income	1,524,708	1,443,124
Franking credit	408,091	-
TOTAL FINANCE INCOME	3,718,050	4,336,268
FINANCE COSTS		
Investment management fees	156,698	150,895
Bank charges	6,978	22,440
Foreign exchange loss	-	165
TOTAL FINANCE COSTS	163,676	173,500
TOTAL NET FINANCE INCOME	3,554,374	4,162,768

	2025	2024
	\$	\$
Note 10 Cash and cash equivalents		
Cash on hand	-	10,050
Bank balances	6,186,274	5,309,764
TOTAL CASH AND CASH EQUIVALENTS	6,186,274	5,319,814

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

	2025	2024
	\$	\$
Note 11 Trade and other receivables		
Trade receivables	1,747,905	4,975,860
Prepayments	486,361	436,869
Related party receivables - Mindgardens	-	44,420
TOTAL TRADE AND OTHER RECEIVABLES	2,234,266	5,457,149
	2025	2024
	\$	\$
Note 12 Other financial assets		
Investments	38,292,938	40,970,363
TOTAL OTHER FINANCIAL ASSETS	38,292,938	40,970,363

Note 13 Property, plant and equipment

Leasehold Improvements

The Medical Research Buildings are located on State Crown land managed by South Eastern Sydney Local Health Network. Rent is \$1 per year and operating expenses, as agreed, are paid annually. The term of the lease is 25 years, terminating on 30 June 2050. All improvements upon the land have been funded by Neuroscience Research Australia through State and Federal Government grants and donations. In 2023, NeuRA was required, under an Order issued by the NSW Department of Planning and Environment, to replace the external cladding on the Margarete Ainsworth Building located at 139 Barker Street, Randwick. The removal of all external cladding was completed during 2025.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

	Building \$	Leasehold improvements \$	Motor vehicles \$	Plant and equipment \$	Furniture and fittings \$	Computer software \$	Computer and electronics \$	Assets under construction \$	Total \$
COST									
BALANCE AT 1 JANUARY 2025	59,597,849	16,573,270	56,799	14,171,754	2,697,763	470,687	1,116,532	36,248	94,720,902
Acquisitions	-	3,506,358	-	487,193	-	-	31,033	-	4,024,584
Reclassification	-	36,248	-	-	-	-	-	(36,248)	-
Disposal	-	-	-	(20,749)	-	(233,000)	(247,327)	-	(501,076)
BALANCE AT 31 DECEMBER 2025	59,597,849	20,115,876	56,799	14,638,198	2,697,763	237,687	900,238	-	98,244,410
DEPRECIATION AND AMORTISATION									
BALANCE AT 1 JANUARY 2025	18,911,026	8,545,015	55,142	11,734,756	2,337,078	363,190	759,248	-	42,705,455
Depreciation/amortisation charge for the year	1,233,129	259,340	372	522,592	70,038	20,366	70,735	-	2,176,572
Disposals	-	-	-	(20,339)	-	(204,678)	(226,539)	-	(451,556)
BALANCE AT 31 DECEMBER 2025	20,144,155	8,804,355	55,514	12,237,009	2,407,116	178,878	603,444	-	44,430,471
CARRYING AMOUNTS									
AT 1 JANUARY 2025	40,686,823	8,028,255	1,657	2,436,998	360,685	107,497	357,284	36,248	52,015,447
AT 31 DECEMBER 2025	39,453,694	11,311,521	1,285	2,401,189	290,647	58,809	296,794	-	53,813,939

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

	2025	2024
	\$	\$
Note 14 Trade and other payables		
Trade payables	255,566	990,207
Other payables and accrued expenditure	6,694,790	1,978,245
TOTAL TRADE AND OTHER PAYABLES	6,950,356	2,968,452

	2025	2024
	\$	\$
Note 15 Employee benefits		
CURRENT		
Liability for annual leave	907,379	1,230,481
Liability for long service leave	928,205	1,761,066
TOTAL CURRENT	1,835,584	2,991,547
NON-CURRENT		
Liability for long service leave	299,987	348,675
TOTAL NON-CURRENT	299,987	348,675

Note 16 List of subsidiaries

Set out below is a list of controlled entities of the Company.

	2025	2024
	%	%
Neuroscience Research Australia is the ultimate parent entity		
CONTROLLED ENTITIES		
Neuroscience Research Australia Foundation (Charitable Trust)	100	100
Schizophrenia Research Institute	100	100

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

Note 17 Related parties

a) Parent and ultimate controlling party

The ultimate controlling party of the Group is Neuroscience Research Australia.

b) Transactions with key management personnel

In addition to their salaries, the Group contributes to accumulation contribution superannuation funds on their behalf.

Key management personnel compensation

The key management personnel compensation included in 'personnel expenses' (Note 6) are as follows:

	2025	2024
	\$	\$
Total key management personnel compensation	1,341,087	1,287,267

No other key management transactions outside those notes were identified during the year.

c) Identity of related parties

The Group has a related party relationship with its controlled entities, associates, and with its key management personnel.

	2025	2024
	\$	\$
d) Other related party transactions		
Mindgardens - Salaries	286,740	303,079
Funds received from Neuroscience Research Australia Foundation	4,155,938	4,411,258
South Eastern Sydney Local Health Network- Rent paid	1	1
UNSW- Infrastructure funds received	1,960,274	2,174,802
UNSW- Grants received	9,806,176	8,211,518
UNSW- Lab consumables and other purchases	770,596	513,703
South Eastern Sydney Health Revenue	5,455	-
UNSW Expenses	765,390	586,256
South Eastern Sydney Health Expenses	794,490	1,098,817

	2025	2024
	\$	\$

Note 18 Auditor's remuneration

AUDIT SERVICES

Audit of financial statements	69,208	62,773
Audit of Foundation Public Ancillary Fund Compliance	3,376	3,271
	72,584	66,044

OTHER SERVICES

Compilation of financial statements	11,816	11,447
Charitable Fundraising Act Procedures	3,376	3,271
	15,192	14,718

TOTAL AUDITOR'S REMUNERATION	87,776	80,762
-------------------------------------	---------------	---------------

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

	2025	2024
	\$	\$
Note 19 Capital and other commitments		
Within one year	14,050	14,050
One year or later and no later than five	26,548	40,598
	40,598	54,648

Commitments are in relation to the operating lease of photocopiers.

Note 20 Parent entity disclosures

As at, and throughout, the financial year ended 31 December 2025 the parent entity of the Group was Neuroscience Research Australia.

	2025	2024
	\$	\$
Results of the parent entity		
(Loss)/surplus of the parent entity	(7,648,937)	1,117,477
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	(7,648,937)	1,117,477
Financial position of the parent entity at year end		
Current assets	44,552,343	31,570,461
Total assets	98,366,282	88,383,378
Current liabilities	(22,374,341)	(8,364,980)
Total liabilities	(26,345,495)	(8,713,655)
Total members' funds to the parent entity comprising of:		
Retained surplus	72,020,787	79,669,723
TOTAL MEMBERS' FUNDS	72,020,787	79,669,723

Note 21 Subsequent events

In March 2026, the Group deregistered the Schizophrenia Research Institute (SRI) as a subsidiary.

Other than the matters discussed above, there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the directors of the Group, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group, in future financial years.

Notes to the Consolidated Financial Statements

For the year ended 31 December 2025

Note 22 Fundraising appeals conducted during the financial period by the Neuroscience Research Australia

During the period, fundraising appeals conducted by the Neuroscience Research Australia for the acceptance of donations.

	2025	2024
	\$	\$
RESULTS OF FUNDRAISING APPEALS		
Gross proceeds from fundraising	9,319,795	8,637,626
Less: direct costs of fundraising	(2,437,553)	(2,220,469)
NET SURPLUS OBTAINED FROM FUNDRAISING APPEALS	6,882,242	6,417,157
This surplus was allocated to:		
Expenditure on research	4,155,938	4,411,258
Transfer of accumulated funds for future research expenditure	2,726,304	2,005,899
TOTAL ALLOCATION	6,882,242	6,417,157


Directors' Declaration

In the opinion of the Directors of Neuroscience Research Australia (the 'Company'):

- a) The consolidated financial statements and notes that are set out on pages 9 to 25 are in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, including:
 - i) giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance, for the financial year ended on that date; and
 - ii) complying with Australian Accounting Standards - Simplified Disclosure Requirements and the *Australian Charities and Not-for-Profits Commission Act 2012*.
- b) There are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

Dated at Sydney this 14th day of May 2026.


James MacNevin
Chairman


Prof Matthew Kiernan AM
Chief Executive Officer


Declaration by Responsible Officer in Respect of Fundraising Appeals

For the year ended 31 December 2025

I, Matthew Kiernan, Chief Executive Officer and responsible officer of Neuroscience Research Australia, declare in my opinion that:

- a) the financial report gives a true and fair view of all income and expenditure of Neuroscience Research Australia with respect to fundraising appeal activities for the year ended 31 December 2025;
- b) the statement of financial position gives a true and fair view of the state of affairs with respect to fundraising appeal activities for the year ended 31 December 2025;
- c) the provisions of the *Charitable Fundraising Act 1991* (NSW) and the conditions attached to the authority have been complied with for the year ended 31 December 2025; and
- d) the internal controls exercised by Neuroscience Research Australia are appropriate and effective in accounting for all income received and applied from any fundraising appeals.

Dated at Sydney this 14th day of May 2026.



Prof Matthew Kiernan AM
Chief Executive Officer



Independent Auditor's Report

To the members of Neuroscience Research Australia

Opinion

We have audited the **Financial Report**, of Neuroscience Research Australia (the Company).

In our opinion the accompanying Financial Report of the Company is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission (ACNC) Act 2012*, and sections 23(1)(d) and 24B of the *Charitable Fundraising Act (NSW) 1991*, including:

- i. giving a true and fair view of the **Group's** financial position as at 31 December 2025, and of its financial performance and its cash flows for the year ended on that date; and
- ii. complying with *Australian Accounting Standards – Simplified Disclosures Framework* and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022 (ACNCR)* and section 21 of the *Charitable Fundraising Regulation (NSW) 2021*.

The **Financial Report** comprises:

- i. Consolidated statement of financial position as at 31 December 2025.
- ii. Consolidated statement of profit or loss and other comprehensive income, Consolidated statement of changes in members' funds, and Consolidated statement of cash flows for the year then ended.
- iii. Notes, including a summary of material accounting policies.
- iv. Declaration by the Directors
- v. Declaration by Responsible officer in respect of the fundraising appeals.

The **Group** consists of the Company and the entities it controlled at the year-end or from time to time during the financial year.

Basis for opinion

We conducted our audit in accordance with *Australian Auditing Standards*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *ACNC Act 2012* and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the Financial Report in Australia. We have fulfilled our other ethical responsibilities in accordance with these requirements.

Other information

Other Information is financial and non-financial information in Neuroscience Research Australia's annual report which is provided in addition to the Financial Report and the Auditor's Report. The Directors are responsible for the Other Information.

Our opinion on the Financial Report does not cover the Other Information and, accordingly, we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Report, our responsibility is to read the Other Information. In doing so, we consider whether the Other Information is materially inconsistent with the Financial Report, or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We are required to report if we conclude that there is a material misstatement of this Other Information and based on the work we have performed on the Other Information that we obtained prior to the date of this Auditor's Report we have nothing to report.

Responsibilities of the Directors for the Financial Report

The Directors are responsible for:

- i. preparing the Financial Report that gives a true and fair view in accordance with Australian Accounting Standards - *Simplified Disclosures Framework* and the *ACNC and ACNCR* and sections 23(1)(d) and 24B of the *Charitable Fundraising Act (NSW) 1991* and section 21 of the *Charitable Fundraising Regulation (NSW) 2021*.
- ii. implementing necessary internal control to enable the preparation of a Financial Report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
- iii. assessing the Group and Company's ability to continue as a going concern and whether the use of the going concern basis of accounting is appropriate. This includes disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless they either intend to liquidate the Group and Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Report

Our objective is:

- i. to obtain reasonable assurance about whether the Financial Report as a whole is free from material misstatement, whether due to fraud or error; and
- ii. to issue an Auditor's Report that includes our opinion.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with *Australian Auditing Standards* will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error. They are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Report.

As part of an audit in accordance with *Australian Auditing Standards*, we exercise professional judgement and maintain professional scepticism throughout the audit.



We also:

- i. Identify and assess the risks of material misstatement of the Financial Report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ii. Obtain an understanding of internal control relevant to the Audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the registered Group's internal control.
- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- iv. Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the registered Group and Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Financial Report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the registered Group and Company to cease to continue as a going concern.
- v. Evaluate the overall presentation, structure and content of the Financial Report, including the disclosures, and whether the Financial Report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Directors of the registered Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

KPMG

KPMG

Warwick Shanks

Partner

Sydney

14 May 2026